Vasopressin secretion control: Central neural pathways, neurotransmitters and effects of drugs

Current Pharmaceutical Design

Volumn 18, Issue 30, 2012, Pages 4714-4724

  Iovino, Michele ^a   Guastamacchia, Edoardo ^a   Giagulli, Vito Angelo ^a   Licchelli, Brunella ^a   Triggiani, Vincenzo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Baroreceptors; Circumventricular organs; Osmolality; Osmoreceptors; Vasopressin

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN 1 RECEPTOR; ATROPINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHLORAMPHETAMINE; DOPAMINE; DYNORPHIN; ENKEPHALIN; FENFLURAMINE; HEXAMETHONIUM; MECAMYLAMINE; METOCLOPRAMIDE; MUSCIMOL; NEUROTRANSMITTER; NORADRENALIN; OPIATE ANTAGONIST; OXOTREMORINE; OXYTOCIN; PIRENZEPINE; QUINPIROLE; QUIPAZINE; RELAXIN; SEROTONIN; SPIPERONE; SULPIRIDE; VASOPRESSIN;

AORTA PRESSORECEPTOR; AREA POSTREMA; BLOOD BRAIN BARRIER; DOPAMINE BLOOD LEVEL; DOPAMINERGIC SYSTEM; HUMAN; HYPOTHALAMUS; LOCUS CERULEUS; NONHUMAN; OXYTOCIN RELEASE; PRESSORECEPTOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE;

ANIMALS; HUMANS; NEURAL PATHWAYS; NEUROTRANSMITTER AGENTS; OSMOLAR CONCENTRATION; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; PITUITARY GLAND, POSTERIOR; RECEPTORS, VASOPRESSIN; VASOPRESSINS; WATER-ELECTROLYTE BALANCE;

EID: 84866398630     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802651607     Document Type: Review

References (186)

1. Swaab DF, Pool CW, Nijveldt F. Immunofluorescence of vasopressin and oxytocin in the rat hypothalamoneurohypophypopseal system. J Neural Transm 1975; 36(3-4): 195-215.
2. Vandesande F, Dierickx K. Identification of the vasopressin producing and of the oxytocin producing neurons in the hypothalamic magnocellular neurosecretroy system of the rat. Cell Tissue Res 1975; 164(2): 153-162.
3. Ochs S. Axoplasmic transport in peripheral nerve and hypothalamo- neurohypophyseal systems. Adv Exp Med Biol 1977; 87: 13-40.
4. Altura BM, Altura BT. Vascular smooth muscle and neurohypophyseal hormones. Fed Proc 1977; 36(6): 1853-1860.
5. Cowley AW. Vasopressin and cardiovascular regulation. In: Guyton AC, Hall JE. eds. International Review of Physiology, Baltimore, University Park Press 1982; 26: 189-242.
6. Surget A, Belzung C. Involvement of vasopressin in affective disorders. Eur J Pharmacol 2008; 583(2-3): 340-349.
7. Born J, Pietrowsky R, Fehm HL.Neuropsychological effects of vasopressin in healthy humans. Prog Brain Res 1998; 119: 619-643.
8. Tatro JB. Endogenous antipyretics. Clin Infect Dis 2000; 31 Suppl 5: S190-201.
9. Veale WL, Cooper KE, Ruwe WD. Vasopressin: its role in antipyresis and febrile convulsion. Brain Res Bull 1984; 12(2): 161-165.
10. Wilkinson MF, Horn TF, Kasting NW, Pittman QJ. Central interleukin-1 beta stimulation of vasopressin release into the rat brain: activation of an antipyretic pathway. J Physiol 1994; 481 (Pt 3): 641-646.
11. Pittman QJ, Wilkinson MF. Central arginine vasopressin and endogenous antipyresis. Can J Physiol Pharmacol 1992; 70(5): 786-790.
12. Richmond CA. The role of arginine vasopressin in thermoregulation during fever. J Neurosci Nurs 2003; 35(5): 281-286.
13. Verbalis JG. Osmotic inhibition of neurohypophysial secretion. Ann N Y Acad Sci 1993; 689: 146-160.
14. Robertson GL, Athar S, Shelton RL. Osmotic control of vasopressin function. In: TE Andreoli, JJ Grantham and CR Floyd. Disturbances in body fluid osmolality. The Williams and Wilkins Co., Baltimore 1977; pp. 125-149.
15. Caillens H, Pruszcynski W, Meyrier A. Relationship between change in volemia at constant osmolality and plasma antidiuretic hormone. Mineral Electrolyte Metab 1980; 4: 161-171.
16. Dellmann HD, Simpson JB. Int Rev Cytol 1979; 58: 333-421.
17. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul Pharmacol 2002; 38(6): 323-337.
18. Mullier A, Bouret SG, Prevot V, Dehouck B. Differential distribution of tight junction proteins suggests a role for tanycytes in blood-hypothalamus barrier regulation in the adult mouse brain. J Comp Neurol 2010; 518(7): 943-962.
19. Miselis RR. The efferent projections of the subfornical organ of the rat: a circumventricular organ within a neural network subserving water balance. Brain Res 1981; 230(1-2): 1-23.
20. Lind RW, Van Hoesen GW, Johnson AK. An HRP study of the connections of the subfornical organ of the rat. J Comp Neurol 1982; 210(3): 265-277.
21. Renaud LP, Rogers J, Sgro S. Terminal degeneration in supraoptic nucleus following subfornical organ lesions: ultrastructural observations in the rat. Brain Res 1983; 275(2): 365-368.
22. Ferguson AV, Kasting NW. Electrical stimulation in subfornical organ increases plasma vasopressin concentrations in the conscious rat. Am J Physiol 1986; 251(2 Pt 2): R425-R428.
23. Lind RW, Johnson AK. Subfornical organ-median preoptic connections and drinking and pressor responses to angiotensin II. J Neurosci 1982; 2(8): 1043-1051.
24. Simpson JB, Mangiapane ML, Dellmann HD. Central receptor sites for angiotensin-induced drinking: a critical review. Fed Proc 1978; 37(13): 2676-2682.
25. Tanaka J, Kaba H, Saito H, Seto K. Subfornical organ neurons with efferent projections to the hypothalamic paraventricular nucleus: an electrophysiological study in the rat. Brain Res 1985; 346(1): 151-154.
26. Landas S, Phillips MI, Stamler JF, Raizada MK. Visualization of specific angiotensin II binding sites in the brain by fluorescent microscopy. Science 1980; 210(4471): 791-793.
27. Sirett NE, McLean AS, Bray JJ, Hubbard JI. Distribution of angiotensin II receptors in rat brain. Brain Res 1977; 122(2): 299-312.
28. Abdelaal AE, Assaf SY, Kucharczyk J, Mogenson GJ. Effect of ablation of the subfornical organ on water intake elicited by systemically administered angiotensin-II. Can J Physiol Pharmacol 1974; 52(6): 1217-1220.
29. Simpson JB, Routtenberg A. Subfornical organ: site of drinking elicitation by angiotensin II. Science 1973; 181(4105): 1172-1175.
30. Hoffman WE, Phillips MI, Schmid P. The role of catecholamines in central antidiuretic and pressor mechanisms. Neuropharmacology 1977; 16(9): 563-569.
31. Keil LC, Summy-Long J, Severs WB. Release of vasopressin by angiotensin II. Endocrinology 1975; 96(4): 1063-1065.
32. Knepel W, Nutto D, Anhut H, Hertting G. Vasopressin and betaendorphin release after osmotic and nonosmotic stimuli: effect of naloxone and dexamethasone. Eur J Pharmacol 1982; 77(4): 299-306.
33. Yamaguchi K, Hama H, Sakaguchi T, Negoro H, Kamoi K. Effects of intraventricular injection of Sar1-Ala8-angiotensin II on plasma vasopressin level increased by angiotensin II and by water deprivation in conscious rats. Acta Endocrinol (Copenh) 1980; 93(4): 407-412.
34. Iovino M, Steardo L. Vasopressin release to central and peripheral angiotensin II in rats with lesions of the subfornical organ. Brain Res 1984; 322(2): 365-368.
35. Knepel W, Nutto D, Meyer DK. Effect of transection of subfornical organ efferent projections on vasopressin release induced by angiotensin or isoprenaline in the rat. Brain Res 1982; 248(1): 180-184.
36. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52(3): 415-472.
37. Kaschina E, Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 2003; 12(2): 70-88.
38. Li XC, Shao Y, Zhuo JL. AT1a receptor knockout in mice impairs urine concentration by reducing basal vasopressin levels and its receptor signaling proteins in the inner medulla. Kidney Int 2009; 76(2): 169-177.
39. Schrier RW. Interactions between angiotensin II and arginine vasopressin in water homeostasis. Kidney Int 2009; 76(2): 137-139.
40. Weindl A, Sofroniew MV. Relation of neuropeptides to mammalian circumventricular organs. In: Martin JB, Reichlin S. and Bick KL. Neurosecretion and Brain Peptides, Raven Press, New York, 1981, pp. 303-320.
41. Miselis R., Hyde TM, Shapiro RE. Disturbance in water balance controls following lesions to the area postrema and adjacent solitary nucleus. In: De Caro G, Epstein AN and Massi M. The Physiology of Thirst and Sodium Appetite, Plenum Press, New York, 1986, pp. 279-285.
42. Iovino M, Papa M, Monteleone P, Steardo L. Neuroanatomical and biochemical evidence for the involvement of the area postrema in the regulation of vasopressin release in rats. Brain Res 1988; 447(1): 178-182.
43. Camacho A, Phillips MI. Horseradish peroxidase study in rat of the neural connections of the organum vasculosum of the lamina terminalis. Neurosci Lett 1981; 25(3): 201-204.
44. Sawchenko PE, Swanson LW. The organization of forebrain afferents to the paraventricular and supraoptic nuclei of the rat. J Comp Neurol 1983; 218(2): 121-144.
45. Thrasher TN, Keil LC, Ramsay DJ. Lesions of the organum vasculosum of the lamina terminalis (OVLT) attenuate osmoticallyinduced drinking and vasopressin secretion in the dog. Endocrinology 1982; 110(5): 1837-1839.
46. McKinley MJ, Mathai ML, McAllen RM, et al. Vasopressin secretion: osmotic and hormonal regulation by the lamina terminalis. J Neuroendocrinol 2004; 16(4): 340-347.
47. Black SL, Mogenson GJ. The regulation of serum sodium in septal lesioned rats: a test of two hypotheses. Physiol Behav 1973; 10(2): 379-384.
48. Mogenson GJ. Septal-hypothalamic relationships. In: DeFrance JF. The Septal Nuclei; Plenum Press, New York, 1976; pp. 149-184.
49. Tondat LM, Almli CR. Hyperdipsia produced by severing ventral septal fiber systems. Physiol Behav 1975; 15(6): 701-706.
50. Iovino M, Monteleone P, Papa M, Amoruso A, Steardo L. Selective damage of neuron perikarya in the medial septum of the rat forebrain: effects on food and water intake, urine output and body weight. Neurosci Res 1988; 6(1): 76-82.
51. Iovino M, Poenaru S, Annunziato L. Basal and thirst-evoked vasopressin secretion in rats with electrolytic lesion of the medioventral septal area. Brain Res 1983; 258(1): 123-126.
52. Tangapregassom AM, Tangapregassom MJ, Soulairac A, Soulairac ML. Effects of septal lesions on the ultrastructure of the supra-optic nucleus. Ann Endocrinol (Paris) 1974; 35(2): 149-152.
53. Záborszky L, Léránth C, Makara GB, Palkovits M. Quantitative studies on the supraoptic nucleus in the rat. II. Afferent fiber connections. Exp Brain Res 1975; 22(5): 525-540.
54. Faraci WS, Yang BV, O'Rourke D, Spencer RW. Septal projections to nuclei functioning in oxytocin release. Am J Anat 1967; 120(3): 605-610.
55. Iovino M, Papa M, Monteleone P, Steardo L. Changes in magnocellular neurosecretory activity following septal forebrain lesions: morphological and biochemical data. Neuro endocrinol. Lett 1989; 11(6): 361-369.
56. Bridge JG, Hatton GI. Septal unit activity in response to alterations in blood volume and osmotic pressure. Physiol Behav 1973; 10(4): 769-774.
57. Iovino M, Steardo L. The role of the septal area in the regulation of drinking behaviour and plasma ADH secretion. In: De Caro G, Epstein AN and Massi M. The Physiology of Thirst and Sodium Appetite. Plenum Press, New York 1986; pp. 367-374.
58. Iovino M, Steardo L. Effects of septal lesions on the response of vasopressin to angiotensin II. Ann Endocrinol (Paris) 1985; 46(2): 113-117.
59. Kalia MP. Localization of aortic and carotid baroreceptor and chemoreceptor primary afferents in the brain stem. In: Buckely JP and Ferrario CM. Central Nervous System Mechanisms in Hypertension. Raven Press, New York 1981; pp.9-24.
60. Palkovits M and Zaborszky L. Neuroanatomy of central cardiovascular control. Nucleus tractus solitarius: afferent and efferent connections in relation to baroreceptor reflex arch. In: DeJong W, Prevoost AP and Shapiro AP. Hypertension and Brain Mechanisms, Elsevier, Amsterdam 1977; pp. 9-34.
61. Koizumi K, Yamashita H. Influence of atrial stretch receptors on hypothalamic neurosecretory neurones. J Physiol 1978; 285: 341-358.
62. Dahlstroem A, Fuxe K. Evidence for the existence of monoaminecontaining neurons in the central nervous system. I demonstration of monoamines in the cell bodies of brain stem neurons. Acta Physiol Scand Suppl 1964; 62 [Suppl 232]: 1-80.
63. Hökfelt T, Fuxe K, Goldstein M, Johansson O. Immunohistochemical evidence for the existence of adrenaline neurons in the rat brain. Brain Res 1974; 66 (suppl. 232): 235-251.
64. Iovino M, Vanacore A, Steardo L. Alpha 2-adrenergic stimulation within the nucleus tractus solitaries attenuates vasopressin release induced by depletion of cardiovascular volume. Pharmacol Biochem Behav 1990; 37(4): 821-824.
65. Sved AF, Imaizumi T, Talman WT, Reis DJ. Vasopressin contributes to hypertension caused by nucleus tractus solitarius lesions. Hypertension 1985; 7(2): 262-267.
66. Kalia M, Mesulam MM. Brain stem projections of sensory and motor components of the vagus complex in the cat: I. The cervical vagus and nodose ganglion. J Comp Neurol 1980; 193(2): 435-465.
67. Norgren R. Projections from the nucleus of the solitary tract in the rat. Neuroscience 1978; 3(2): 207-218.
68. Sawchenko PE, Swanson LW. The organization of noradrenergic pathways from the brainstem to the paraventricular and supraoptic nuclei in the rat. Brain Res 1982; 257(3): 275-325.
69. Day TA, Renaud LP. Electrophysiological evidence that noradrenergic afferents selectively facilitate the activity of supraoptic vasopressin neurons. Brain Res 1984; 303(2): 233-240.
70. Yamane Y, Nakai M, Yamamoto J, Umeda Y, Ogino K. Release of vasopressin by electrical stimulation of the intermediate portion of the nucleus of the tractus solitarius in rats with cervical spinal cordotomy and vagotomy. Brain Res 1984; 324(2): 358-360.
71. Palkovits M. Catecholamines in the hypothalamus: an anatomical review. Neuroendocrinology 1981; 33(2): 123-128.
72. Forsling ML, Williams H. Central effects of dopamine on vasopressin release in the normally hydrated and water-loaded rat. J Physiol 1984; 346: 49-59.
73. Iványi T, Laczi F, Kovács GL, et al. Stimulatory effect of intracerebroventricularly administered dopamine on vasopressin release in rats Exp. Exp Clin Endocrinol 1986; 88(3): 303-308.
74. Bridges TE, Hillhouse EW, Jones MT. The effect of dopamine on neurohypophysial hormone release in vivo and from the rat neural lobe and hypothalamus in vitro. J Physiol 1976; 260(3): 647-666.
75. Yamaguchi K, Hama H. Participation of periventricular dopamine receptors in vasopressin secretion elicited by hypertonicity of systemic blood in rats. Acta Endocrinol (Copenh) 1991; 124(4): 455-462.
76. Moos F, Richard P. Excitatory effect of dopamine on oxytocin and vasopressin reflex releases in the rat. Brain Res 1982; 241(2): 249-260.
77. Oki Y, Ohgo S, Yoshimi T. Effects of water deprivation and administration of hypertonic saline on dopamine concentrations in posterior pituitary and vasopressin release in rats. Brain Res 1985; 348(1): 9-14.
78. Yang CR, Bourque CW, Renaud LP. Dopamine D2 receptor activation depolarizes rat supraoptic neurones in hypothalamic explants. J Physiol 1991; 443: 405-419.
79. Lightman SL, Todd K, Everitt BJ. Ascending noradrenergic projections from the brainstem: evidence for a major role in the regulation of blood pressure and vasopressin secretion. Exp Brain Res 1984; 55(1): 145-151.
80. Alonso G, Szafarczyk A, Balmefrézol M, Assenmacher I. Immunocytochemical evidence for stimulatory control by the ventral noradrenergic bundle of parvocellular neurons of the paraventricular nucleus secreting corticotropin releasing hormone and vasopressin in rats. Brain Res 1986; 397(2): 297-307.
81. Head GA, Quail AW, Woods RL. Lesions of A1 noradrenergic cells affect AVP release and heart rate during hemorrhage. Am J Physiol 1987; 253(5 Pt 2): H1012-H1017.
82. Day TA, Ferguson AV, Renaud LP. Facilitatory influence of noradrenergic afferents on the excitability of rat paraventricular nucleus neurosecretory cells. J Physiol 1984; 355: 237-249.
83. Tanaka J, Kaba H, Saito H, Seto K. Inputs from the A1 noradrenergic region to hypothalamic paraventricular neurons in the rat. Brain Res 1985; 335(2): 368-371.
84. Day TA. Control of neurosecretory vasopressin cells by noradrenergic projections of the caudal ventrolateral medulla. Prog Brain Res 1989; 81: 303-317.
85. Day TA, Randle JC, Renaud LP. Opposing alpha- and betaadrenergic mechanisms mediate dose-dependent actions of noradrenaline on supraoptic vasopressin neurones in vivo. Brain Res 1985; 358(1-2): 171-179.
86. Brooks DP, Share L, Crofton JT. Central adrenergic control of vasopressin release. Neuroendocrinology 1986; 42(5): 416-420.
87. Leibowitz SF, Eidelman D, Suh JS, Diaz S, Sladek CD. Mapping study of noradrenergic stimulation of vasopressin release. Exp Neurol 1990; 110(3): 298-305.
88. Knigge U, Willems E, Kjaer A, Jørgensen H, Warberg J. Histaminergic and catecholaminergic interactions in the central regulation of vasopressin and oxytocin secretion. Endocrinology 1999; 140(8): 3713-3719.
89. Armstrong WE, Gallagher MJ, Sladek CD. Noradrenergic stimulation of supraoptic neuronal activity and vasopressin release in vitro: mediation by an alpha 1-receptor. Brain Res 1986; 365(1): 192-197.
90. Radács M, Gálfi M, Nagyéri G, et al. Significance of the adrenergic system in the regulation of vasopressin secretion in rat neurohypophyseal tissue cultures. Regul Pept 2008; 148(1-3): 1-5.
91. Kapoor JR, Sladek CD. Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release. J Neurosci 2000; 20(23): 8868-8875.
92. Sladek CD, Song Z. Regulation of vasopressin release by coreleased neurotransmitters: mechanisms of purinergic and adrenergic synergism. Prog Brain Res 2008; 170: 93-107.
93. Song Z, Sladek CD. Site of ATP and phenylephrine synergistic stimulation of vasopressin release from the hypothalamoneurohypophyseal system. J Neuroendocrinol 2006; 18(4): 266-272.
94. Sladek CD, Kapoor JR. Neurotransmitter/neuropeptide interactions in the regulation of neurohypophyseal hormone release. Exp Neurol 2001; 171(2): 200-209.
95. Cole RL, Sawchenko PE. Neurotransmitter regulation of cellular activation and neuropeptide gene expression in the paraventricular nucleus of the hypothalamus. J Neurosci 2002; 22(3): 959-969.
96. Yang J, Yuan HF, Liu WY, et al. Norepinephrine regulates arginine vasopressin secretion in hypothalamic paraventricular nucleus relating with pain modulation. Neuropeptides 2009; 43(4): 259-265.
97. Tangapregassom MJ, Tangapregassom AM, Soulairac A. Control mesencephalique du comportament de soif. J Physiol 1973; 67: 413A-5.
98. Tangaprégassom AM, Tangaprégassom MJ, Soulairac A. Effets des lesions de la region du raphe mesencephalique sur le compartament de soif et la neurosecretion hypothalamique anterieure du rat. Ann Endocrinol (Paris) 1974; 35(6): 667-668.
99. Gálfi M, Radács M, Juhász A, László F, Molnár A, László FA. Serotonin-induced enhancement of vasopressin and oxytocin secretion in rat neurohypophyseal tissue culture. Regul Pept 2005; 127(1-3): 225-231.
100. Steardo L, Iovino M. Vasopressin release after enhanced serotonergic transmission is not due to activation of the peripheral reninangiotensin system. Brain Res 1986; 382(1): 145-148.
101. Pérgola PE, Sved AF, Voogt JL, Alper RH. Effect of serotonin on vasopressin release: a comparison to corticosterone, prolactin and renin. Neuroendocrinology 1993; 57(3): 550-558.
102. Iovino M, Steardo L. Effect of substances influencing brain serotonergic transmission on plasma vasopressin levels in the rat. Eur J Pharmacol 1985; 113(1): 99-103.
103. th Annual Meeting of the Society for Neuroscience, Dallas, Texas 1985; p: 20-25.
104. Jørgensen HS. Studies on the neuroendocrine role of serotonin. Dan Med Bull 2007; 54(4): 266-288.
105. Jørgensen H, Riis M, Knigge U, Kjaer A, Warberg J. Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol 2003; 15(3): 242-249.
106. Coiro V, Maffei ML, Volta E, et al Effect of serotonergic system on AVP secretion induced by physical exercise. Neuropeptides 2010; 44(1): 53-56.
107. Theodosis DT, Paut L, Tappaz ML. Immunocytochemical analysis of the GABAergic innervation of oxytocin and vasopressinsecreting neurons in the rat supraoptic nucleus. Neuroscience 1986; 19(1): 207-222.
108. Sladek CD, Joynt RJ. Characterization of cholinergic control of vasopressin release by the organ-cultured rat hypothalamoneurohypophyseal system. Endocrinology 1979; 104(3): 659-663.
109. Zingg HH, Baertschi AJ, Dreifuss JJ. Action of gammaaminobutyric acid on hypothalamo-neurohypophysial axons. Brain Res 1979; 171(3): 453-459.
110. Moss RL, Urban I, Cross BA. Microelectrophoresis of cholinergic and aminergic drugs on paraventricular neurons. Am J Physiol 1972; 223(2): 310-318.
111. Nicoll RA, Barker JL. The pharmacology of recurrent inhibition in the supraoptic neurosecretory system. Brain Res 1971; 35(2): 501-511.
112. Jhamandas JH, Renaud LP. Bicuculline blocks an inhibitory baroreflex input to supraoptic vasopressin neurons. Am J Physiol 1987; 252(5 Pt 2): R947-R952.
113. Jhamandas JH, Renaud LP. A gamma-aminobutyric-acid-mediated baroreceptor input to supraoptic vasopressin neurones in the rat. J Physiol 1986; 381: 595-606.
114. Kombian SB, Zidichouski JA, Pittman QJ. GABAB receptors presynaptically modulate excitatory synaptic transmission in the rat supraoptic nucleus in vitro. J Neurophysiol 1996; 76(2): 1166-1179.
115. Yamaguchi K, Yamada T. Roles of forebrain GABA receptors in controlling vasopressin secretion and related phenomena under basal and hyperosmotic circumstances in conscious rats. Brain Res Bull 2008; 77(1): 61-69.
116. Iovino M, Steardo L, Poenaru S. Inhibitory effect of centrally administered muscimol on increased plasma ADH concentration by angiotensin II. Neuroendocrinology Lett 1982; 4(6): 343-347.
117. Unger T, Bles F, Ganten D, Lang RE, Rettig R, Schwab NA. Gabaergic stimulation inhibits central actions of angiotensin II: pressor responses, drinking and release of vasopressin. Eur J Pharmacol 1983; 90(1): 1-9.
118. Iovino M, De Caro G, Massi M, Steardo L, Poenaru S. Muscimol inhibits ADH release induced by hypertonic sodium chloride in rats. Pharmacol Biochem Behav 1983; 19(2): 335-338.
119. Sladek CD, Armstrong WE. Gamma-Aminobutyric acid antagonists stimulate vasopressin release from organ-cultured hypothalamo-neurohypophyseal explants. Endocrinology 1987; 120(4): 1576-1580.
120. Joanny P, Steinberg J, Guerrero F, Sauze N, Oliver C, Grino M. The effects of ionotropic agonists of excitatory amino acids on the release of arginine vasopressin in rat hypothalamic slices. J Neuroendocrinol 2000; 12(10): 970-976.
121. Otake K, Kondo K, Oiso Y. Possible involvement of endogenous opioid peptides in the inhibition of arginine vasopressin release by gamma-aminobutyric acid in conscious rats. Neuroendocrinology 1991; 54(2): 170-174.
122. Ghuman SP, Prabhakar S, Smith RF, Dobson H. Gamma-amino butyric acid control of arginine vasopressin release from the ewe hypothalamus in vitro: sensitivity to oestradiol. Reprod Domest Anim 2007; 42(5): 527-535.
123. Bali B, Kovács KJ. GABAergic control of neuropeptide gene expression in parvocellular neurons of the hypothalamic paraventricular nucleus. Eur J Neurosci 2003; 18(6): 1518-1526.
124. Chiodera P, Volpi R, Maffei ML, et al. Role of GABA and opioids in the regulation of the vasopressin response to physical exercise in normal men. Regul Pept 1993; 49(1): 57-63.
125. Kim JS, Kim WB, Kim YB, et al. Chronic hyperosmotic stress converts GABAergic inhibition into excitation in vasopressin and oxytocin neurons in the rat. J Neurosci 2011; 31(37): 13312-13322.
126. Soulairac A. The adrenergic and cholinergic control of food and water intake. Ann N Y Acad Sci 1969; 157(2): 934-961.
127. Sladek CD, Joynt RJ. Characterization of cholinergic control of vasopressin release by the organ-cultured rat hypothalamoneurohypophyseal system. Endocrinology 1979; 104(3): 659-663.
128. Sladek CD, Joynt RJ. Cholinergic involvement in osmotic control of vasopressin release by the organcultured rat hypothalamoneurohypophyseal system. Endocrinology 1979; 105(2): 367-371.
129. Cuello AC, Sofroniew MV. The anatomy of the CNS cholinergic neurons. Trends. Neurosci 1984; 7: 74-78.
130. Iitake K, Share L, Ouchi Y, Crofton JT, Brooks DP. Central cholinergic control of vasopressin release in conscious rats. Am J Physiol 1986; 251(2 Pt 1): E146-E150.
131. Iitake K, Share L, Brooks DP, Crofton JT, Ouchi Y. Role of brain acetylcholine in vasopressin release during osmotic stimulation and hemorrhage. Exp Brain Res 1989; 75(1): 47-52.
132. Rascol O, Montastruc JL, Gauquelin G, et al. Cardiovascular effects of central injection of acetylcholine in anaesthetized dogs: a role for vasopressin release. Br J Pharmacol 1990; 100(3): 471-476.
133. Alves FH, Crestani CC, Busnardo C, et al. Hypothalamic supraoptic but not paraventricular nucleus is involved in cardiovascular responses to carbachol microinjected into the bed nucleus of stria terminalis of unanesthetized rats. Brain Res 2011; 1393: 31-43.
134. Xu Z, Ross MG, Johnson AK. Intracerebroventricular carbachol induces FOS immunoreactivity in lamina terminalis neurons projecting to the supraoptic nucleus. Brain Res 2001; 895(1-2): 104-110.
135. Xu Z, Torday J, Yao J. Functional and anatomic relationship between cholinergic neurons in the median preoptic nucleus and the supraoptic cells. Brain Res 2003; 964(2): 171-178.
136. Xu Z, Pekarek E, Ge J, Yao J. Functional relationship between subfornical organ cholinergic stimulation and cellular activation in the hypothalamus and AV3V region. Brain Res 2001; 922(2): 191-200.
137. Bisset GW, Chowdrey HS. A cholinergic link in the reflex release of vasopressin by hypotension in the rat. J Physiol 1984; 354: 523-545.
138. Bisset GW, Chowdrey HS. Control of release of vasopressin by neuroendocrine reflexes. Q J Exp Physiol 1988; 73(6): 811-872.
139. Gregg CM. The compartmentalized hypothalamoneurohypophysial system: evidence for a neurohypophysial action of acetylcholine on vasopressin release. Neuroendocrinology 1985; 40(5): 423-429.
140. Gregg CM. Effect of cholinergic antagonists on basal and osmotically stimulated vasopressin release in compartmentalized hypothalamo-neurohypophysial explants. Neuroendocrinology 1986; 44(3): 378-383.
141. Ota M, Crofton JT, Toba K, Share L. Effect on vasopressin release of microinjection of cholinergic agonists into the rat supraoptic nucleus. Proc Soc Exp Biol Med 1992; 201(2): 208-214.
142. Shoji M, Share L, Crofton JT, Brooks DP. The effect on vasopressin release of microinjection of cholinergic agonists into the paraventricular nucleus of conscious rats. J Neuroendocrinol 1989; 1(6): 401-406.
143. Savci V, Goktalay G, Ulus IH. Intracerebroventricular choline increases plasma vasopressin and augments plasma vasopressin response to osmotic stimulation and hemorrhage. Brain Res 2002; 942(1-2): 58-70.
144. Shioda S, Nakajo S, Hirabayashi T, et al. Neuronal nicotinic acetylcholine receptor in the hypothalamus: morphological diversity and neuroendocrine regulations. Brain Res Mol Brain Res 1997; 49(1-2): 45-54.
145. Shioda S, Yada T, Muroya S, Takigawa M, Nakai Y. Nicotine increases cytosolic Ca2+ in vasopressin neurons. Neurosci Res 1997; 29(4): 311-318.
146. Coiro V, Butturini U, Gnudi A, Delsignore R, Volpi R, Chiodera P. Nicotinic-cholinergic involvement in arginine-vasopressin response to insulin-induced hypoglycemia in normal men. Metabolism 1986; 35(7): 577-579.
147. Coiro V, Capretti L, Speroni G, et al. Muscarinic cholinergic, but not serotoninergic mediation of arginine vasopressin response to metoclopramide in man. Clin Endocrinol (Oxf) 1989; 31(4): 491-498.
148. Steardo L, Iovino M, Monteleone P, Bevilacqua M, Norbiato G. Evidence that cholinergic receptors of muscarinic type may modulate vasopressin release induced by metoclopramide. J Neural Transm Gen Sect 1990; 82(3): 213-2137.
149. Martin R, Voigt KH. Enkephalins co-exist with oxytocin and vasopressin in nerve terminals of rat neurohypophysis. Nature 1981; 289(5797): 502-504.
150. Sar M, Stumpf WE, Miller RJ, Chang KJ, Cuatrecasas P. Immunohistochemical localization of enkephalin in rat brain and spinal cord. J Comp Neurol 1978; 182(1): 17-37.
151. Goldsmith PC, Boggan JE, Thind KK. Opioid synapses on vasopressin neurons in the paraventricular and supraoptic nuclei of juvenile monkeys. Neuroscience 1991; 45(3): 709-719.
152. Rossier J, Pittman Q, Bloom F, Guillemin R. Distribution of opioid peptides in the pituitary: a new hypothalamic-pars nervosa enkephalinergic pathway. Fed Proc 1980; 39(8): 2555-2560.
153. van der Kooy D, Koda LY, McGinty JF, Gerfen CR, Bloom FE. The organization of projections from the cortex, amygdala, and hypothalamus to the nucleus of the solitary tract in rat. J Comp Neurol 1984; 224(1): 1-24.
154. Poulin JF, Chevalier B, Laforest S, Drolet G. Enkephalinergic afferents of the centromedial amygdala in the rat. J Comp Neurol 2006; 496(6): 859-876.
155. Poulain P, Martin-Bouyer L, Beauvillain JC, Tramu G. Study of the efferent connections of the enkephalinergic magnocellular dorsal nucleus in the guinea-pig hypothalamus using lesions, retrograde tracing and immunohistochemistry: evidence for a projection to the lateral septum. Neuroscience 1984; 11(2): 331-343.
156. Bisset GW, Chowdrey HS, Feldberg W. Release of vasopressin by enkephalin. Br J Pharmacol 1978; 62(3): 370-371.
157. Weitzman RE, Fisher DA, Minick S, Ling N, Guillemin R. beta-Endorphin secretion of arginine vasopressin in vivo. Endocrinology 1977; 101(5): 1643-6.
158. Iversen LL, Iversen SD, Bloom FE. Opiate receptors influence vasopressin release from nerve terminals in rat neurohypophysis. Nature 1980; 284(5754): 350-351.
159. Summy-Long JY, Rosella LM, Keil LC. Effects of centrally administered endogenous opioid peptides on drinking behavior, increased plasma vasopressin concentration and pressor response to hypertonic sodium chloride. Brain Res 1981; 221(2): 343-357.
160. Summy-Long JY, Miller DS, Rosella-Dampman LM, Hartman RD, Emmert SE. A functional role for opioid peptides in the differential secretion of vasopressin and oxytocin. Brain Res 1984; 309(2): 362-366.
161. ten Haaf JA, van Wimersma Greidanus TB, Maigret C, De Wied D. Effect of the opioid peptide betaendorphin on the in vivo release of vasopressin in rats under various conditions. Neuroendocrinology 1986; 44(1): 102-107.
162. Lightman SL, Iversen LL, Forsling ML. Dopamine and [D-ALA2, D-Leu5]enkephalin inhibit the electrically stimulated neurohypophyseal release of vasopressin in vitro: evidence for calciumdependent opiate action. J Neurosci 1982; 2(1): 78-81.
163. Iovino M, Rouhani S, Poenaru S. Dual effect of met-enkephalin on plasma ADH concentration in the rat. Neuroendocrinol Lett 1983; 4, 239-243.
164. Keil LC, Rosella-Dampman LM, Emmert S, Chee O, Summy-Long JY. Enkephalin inhibition of angiotensin-stimulated release of oxytocin and vasopressin. Brain Res 1984; 297(2): 329-336.
165. Yamada T, Nakao K, Itoh H, et al. Opioid modulation of vasopressin secretion in conscious rats. Clin Exp Hypertens A 1988; 10 Suppl 1: 361-367.
166. Yamada T, Nakao K, Itoh H, Shirakami G, Sugawara A, Saito Y, Mukoyama M, Arai H, Hosoda K, Shiono S. Effects of naloxone on vasopressin secretion in conscious rats: evidence for inhibitory role of endogenous opioid peptides in vasopressin secretion. Endocrinology 1989; 125(2): 785-790.
167. Matsui K, Kimura T, Ota K, et al. Attenuation of the osmotic release of vasopressin by enkephalins in dogs. Am J Physiol 1989; 256(2 Pt 1): E270-E276.
168. Wang XM, Tresham JJ, Congiu M, Scoggins BA, Coghlan JP. Central effect of the enkephalin analogue FK-33824 on vasopressin secretion in conscious sheep. Acta Endocrinol (Copenh) 1989; 120(3): 369-373.
169. Van de Heijning BJ, Koekkoek-Van den Herik I, Maigret C, Van Wimersma Greidanus TB. Pharmacological assessment of the site of action of opioids on the release of vasopressin and oxytocin in the rat. Eur J Pharmacol 1991; 197(2-3): 175-180.
170. Lessard A, Bachelard H. Tonic inhibitory control exerted by opioid peptides in the paraventricular nuclei of the hypothalamus on regional hemodynamic activity in rats. Br J Pharmacol 2002; 136(5): 753-763.
171. Grossman A, Clement-Jones V. Opiate receptors: enkephalins and endorphins. Clin Endocrinol Metab.1983; 12(1): 31-56.
172. Hamon G, Jouquey S. Kappa agonists and vasopressin secretion. Horm Res 1990; 34(3-4): 129-132.
173. Leander JD, Hart JC, Zerbe RL. Kappa agonist-induced diuresis: evidence for stereoselectivity, strain differences, independence of hydration variables and a result of decreased plasma vasopressin levels. J Pharmacol Exp Ther 1987; 242(1): 33-39.
174. Oiso Y, Iwasaki Y, Kondo K, Takatsuki K, Tomita A. Effect of the opioid kappa-receptor agonist U50488H on the secretion of arginine vasopressin. Study on the mechanism of U50488H-induced diuresis. Neuroendocrinology 1988; 48(6): 658-662.
175. Zhao BG, Chapman C, Bicknell RJ. Functional kappa-opioid receptors on oxytocin and vasopressin nerve terminals isolated from the rat neurohypophysis. Brain Res 1988; 462(1): 62-66.
176. Leng G, Bicknell RJ, Brown D, Bowden C, Chapman C, Russell JA. Stimulus-induced depletion of pro-enkephalins, oxytocin and vasopressin and pro-enkephalin interaction with posterior pituitary hormone release in vitro. Neuroendocrinology 1994; 60(6): 559-566.
177. Shuster SJ, Riedl M, Li X, Vulchanova L, Elde R. The kappa opioid receptor and dynorphin co-localize in vasopressin magnocellular neurosecretory neurons in guinea-pig hypothalamus. Neuroscience 2000; 96(2): 373-383.
178. Scott V, Bishop VR, Leng G, Brown CH. Dehydration-induced modulation of kappa-opioid inhibition of vasopressin neurone activity. J Physiol 2009; 587(Pt 23): 5679-5689.
179. Puritz R, Lightman SL, Wilcox CS, Forsling M, Bannister R. Blood pressure and vasopressin in progressive autonomic failure. Response to postural stimulation, L-dopa and naloxone. Brain 1983; 106 (Pt 2): 503-511.
180. Zerbe RL, Henry DP, Robertson GL. Vasopressin response to orthostatic hypotension. Etiologic and clinical implications. Am J Med 1983; 74(2): 265-271.
181. Norbiato G, Bevilacqua M, Righini V, et al. Altered vasopressin response to metoclopramide in multiple system atrophy: evidence of a cholinergic defect in the hypothalamus. Acta Neurol Scand 1992; 85(4): 299-303.
182. Kaufmann H, Oribe E, Miller M, Knott P, Wiltshire-Clement M, Yahr MD. Hypotension-induced vasopressin release distinguishes between pure autonomic failure and multiple system atrophy with autonomic failure. Neurology 1992; 42: 590-593.
183. Iovino M, Triggiani V, Licchelli B, et al. Vasopressin release induced by hypothension is blunted in patients with diabetic autonomic neuropathy. Immunopharmacol Immunotoxicol 2011; 33(1):224-226.
184. Radács M, Gálfi M, Nagyéri G, Molnár AH, Varga C, László F, László FA. Significance of the adrenergic system in the regulation of vasopressin secretion in rat neurohypophyseal tissue cultures. Regul Pept 2008; 148(1-3): 1-5.
185. Willoughby JO, Jervois PM, Menadue MF, Blessing WW. Noradrenaline, by activation of alpha-1-adrenoceptors in the region of the supraoptic nucleus, causes secretion of vasopressin in the unanaesthetized rat. Neuroendocrinology 1987; 45(3): 219-226.
186. Jørgensen HS. Studies on the neuroendocrine role of serotonin. Dan Med Bull 2007; 54(4): 266-288.